Clementia Pharmaceuticals Inc. Announces Closing of $22.5 Million Series A Financing With Preeminent U.S. and Canadian Healthcare Venture Capital Funds

Corporate Breaking News

Home : Clementia Pharmaceuticals Inc. Announces Closing of $22.5 Million Series A Financing With Preeminent U.S. and Canadian Healthcare Venture Capital Funds

Jan 09 2014	Clementia Pharmaceuticals Inc. Announces Closing of $22.5 Million Series A Financing With Preeminent U.S. and Canadian Healthcare Venture Capital Funds
Company Licenses Exclusive World-Wide Rights to Palovarotene From Roche Pharmaceuticals OrbiMed and BDC Venture Capital Investment to Advance Palovarotene Into Clinical Development for the Treatment of FOP


Source:http://www.marketwired.com/mw/release.do?id=1867583&sourceType=3

Related News
» Cobalt Coal Ltd. Announces Receipt of Default Notice from Virginia Property Vendors and Senior Secured Lender » PC Gold Completes Private Placement of Senior Secured Debentures